Monthly
US$200
Billed every month
Moxifloxacin Hydrochloride And Sodium Chloride Injection(盐酸莫西沙星氯化钠注射液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 2 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders39View records ↓
Under-review filings10View records ↓
This year’s generic filers4View records ↓
NHSA approval numbers41View records ↓
API companies with A status0View records ↓
Chemical-drug catalogue
Loaded records: 39 holders; 8 in the quality-and-efficacy consistency-evaluation category, and 30 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 重庆药谷制药有限公司 | 哈尔滨三联药业股份有限公司 | 国药准字H20265222 | 2026/07/21 | 250ml∶盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川太平洋药业有限责任公司 | 四川太平洋药业有限责任公司 | 国药准字H20264988 | 2026/06/30 | 250ml﹕盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 辽宁民康制药有限公司 | 辽宁民康制药有限公司 | 国药准字H20264052 | 2026/04/21 | 250ml∶盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河北凯威恒诚制药有限公司 | 河北天成药业股份有限公司 | 国药准字H20249459 | 2024/12/01 | 250ml：盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖北长联杜勒制药有限公司 | 湖北长联杜勒制药有限公司 | 国药准字H20249516 | 2024/12/01 | 250ml：盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏睿实生物科技有限公司 | 山东裕欣药业有限公司 | 国药准字H20249077 | 2024/10/16 | 250ml：盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东鲁抗医药集团赛特有限责任公司 | 山东鲁抗医药集团赛特有限责任公司 | 国药准字H20249030 | 2024/10/09 | 250ml：盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河北天成药业股份有限公司 | 河北天成药业股份有限公司 | 国药准字H20244974 | 2024/09/26 | 250ml：盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 北京融英医药科技有限公司 | 东莞市普济药业有限公司 | 国药准字H20244544 | 2024/07/30 | 250ml∶盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏长江药业有限公司 | 江苏长江药业有限公司 | 国药准字H20243494 | 2024/04/17 | 250ml:盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 辰欣药业股份有限公司 | 辰欣药业股份有限公司 | 国药准字H20243417 | 2024/03/29 | 250ml：盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆圣华曦药业股份有限公司 | 重庆圣华曦药业股份有限公司 | 国药准字H20243346 | 2024/03/19 | 250ml：盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 贵州阜康仁制药有限公司 | 河北天成药业股份有限公司 | 国药准字H20243201 | 2024/02/23 | 250ml∶盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福建省宝诺医药研发有限公司 | 广东大翔制药有限公司 | 国药准字H20243011 | 2024/01/09 | 250ml∶盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 赤峰源生药业有限公司 | 赤峰源生药业有限公司 | 国药准字H20234509 | 2023/11/21 | 250ml∶盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏悦兴药业有限公司 | 江苏悦兴药业有限公司 | 国药准字H20234493 | 2023/11/21 | 250ml∶盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安徽博诺美科生物医药有限公司 | 上海华源安徽锦辉制药有限公司 | 国药准字H20234176 | 2023/09/19 | 250ml∶盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆世森医药科技有限公司 | 兰西哈三联制药有限公司 | 国药准字H20233958 | 2023/07/25 | 250ml∶盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 西安京西双鹤药业有限公司 | 西安京西双鹤药业有限公司 | 国药准字H20233413 | 2023/04/04 | 250ml:莫西沙星0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆华邦制药有限公司 | 重庆华邦制药有限公司 | 国药准字H20233301 | 2023/03/21 | 250ml：盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 陕西丽彩药业有限公司 | 江苏长江药业有限公司 | 国药准字H20233221 | 2023/02/28 | 250ml∶盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南科伦制药有限公司 | 湖南科伦制药有限公司 | 国药准字H20233218 | 2023/02/28 | 250ml：盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华夏生生药业（北京）有限公司 | 华夏生生药业（北京）有限公司 | 国药准字H20223606 | 2022/08/23 | 250ml：盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江医药股份有限公司 | 浙江医药股份有限公司新昌制药厂 | 国药准字H20223586 | 2022/08/10 | 250ml：盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石药集团欧意药业有限公司 | 石药银湖制药有限公司 | 国药准字H20223552 | 2022/08/08 | 250ml∶盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江西弘惠医药有限公司 | 回音必集团江西东亚制药有限公司 | 国药准字H20223319 | 2022/05/18 | 250ml：莫西沙星0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京正大天晴制药有限公司 | 南京正大天晴制药有限公司 | 国药准字H20203073 | 2021/12/30 | 250ml：盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 四川美大康华康药业有限公司 | 四川美大康华康药业有限公司 | 国药准字H20193171 | 2021/11/12 | 250ml：盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 山东齐都药业有限公司 | 山东齐都药业有限公司 | 国药准字H20193111 | 2021/11/12 | 250ml∶盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 扬子江药业集团有限公司 | 扬子江药业集团有限公司 | 国药准字H20193112 | 2021/02/02 | 250ml：盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 南京恒道医药科技有限公司 | 杭州民生药业有限公司 | 国药准字H20203717 | 2020/12/25 | 250ml:莫西沙星0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H20183411 | 2020/11/23 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 成都正康药业有限公司 | 成都正康药业有限公司 | 国药准字H20183366 | 2020/11/06 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 江苏正大丰海制药有限公司 | 江苏正大丰海制药有限公司 | 国药准字H20183412 | 2020/10/27 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 四川科伦药业股份有限公司 | 四川科伦药业股份有限公司 | 国药准字H20193110 | 2020/10/23 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| — | 海南爱科制药有限公司 | 国药准字H20203091 | 2020/03/11 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| — | 天津红日药业股份有限公司 | 国药准字H20203057 | 2020/02/25 | 250ml: 盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| Bayer Vital GmbH | Bayer AG | H20140424;H20140425 | 2004/04/15 | 250ml:莫西沙星0.4g与氯化钠2.0g | Imported originator drug (进口原研药品) | CDE |
| 北京吉洛华制药有限公司 | 北京吉洛华制药有限公司 | 国药准字H20263525 | 2026/03/10 | 250ml﹕盐酸莫西沙星（按C21H24FN3O4计）0.4g与氯化钠2.0g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 41 distinct approval numbers and 40 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京吉洛华制药有限公司 | 国药准字H20263525 | 250ml﹕盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010100226 | NHSA |
| 天津红日药业股份有限公司 | 国药准字H20203057 | 250ml: 盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010100864 | NHSA |
| 重庆华邦制药有限公司 | 国药准字H20233301 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN3O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010101003 | NHSA |
| 辽宁民康制药有限公司 | 国药准字H20264052 | 250ml∶盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010101227 | NHSA |
| 江苏长江药业有限公司 | 国药准字H20243494 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010101426 | NHSA |
| 江苏正大丰海制药有限公司 | 国药准字H20183412 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010101521 | NHSA |
| 南京正大天晴制药有限公司 | 国药准字H20203073 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010101606 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20234493 | 250ml∶盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010101631 | NHSA |
| 扬子江药业集团有限公司 | 国药准字H20193112 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010101749 | NHSA |
| 成都正康药业有限公司 | 国药准字H20183366 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010102078 | NHSA |
| 四川尚锐生物医药有限公司 | 国药准字H20193171 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010102087 | NHSA |
| 四川科伦药业股份有限公司 | 国药准字H20193110 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010102180 | NHSA |
| 四川太平洋药业有限责任公司 | 国药准字H20264988 | 250ml﹕盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010102261 | NHSA |
| 西安京西双鹤药业有限公司 | 国药准字H20233413 | 250ml:莫西沙星0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010102492 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20244974 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010102662 | NHSA |
| 石家庄四药有限公司 | 国药准字H20183411 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010102763 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H20223552 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010102964 | NHSA |
| 吉林四长制药有限公司 | 国药准字H20213403 | 250ml : 盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010103282 | NHSA |
| 赤峰源生药业有限公司 | 国药准字H20234509 | 250ml∶盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010103871 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20243417 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010104127 | NHSA |
| 山东鲁抗医药集团赛特有限责任公司 | 国药准字H20249030 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010104131 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20193111 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010104145 | NHSA |
| 安徽博诺美科生物医药有限公司 | 国药准字H20234176 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010104435 | NHSA |
| 安徽太阳升药业有限公司 | 国药准字H20203717 | 250ml:莫西沙星0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010104494 | NHSA |
| 黑龙江科朗制药有限公司 | 国药准字H20233218 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010104948 | NHSA |
| 回音必集团江西东亚制药有限公司 | 国药准字H20223319 | 250ml:莫西沙星0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010105251 | NHSA |
| 海南爱科制药有限公司 | 国药准字H20203091 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010105759 | NHSA |
| 浙江医药股份有限公司新昌制药厂 | 国药准字H20223586 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010107968 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20243346 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010109568 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20223606 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010109910 | NHSA |
| Bayer Vital GmbH | 国药准字HJ20140424 | 250ml: 莫西沙星0.4g与氯化钠2.0g。 | Category B (乙) | XJ01MAM134B002010178271 | NHSA |
| 湖北长联杜勒制药有限公司 | 国药准字H20249516 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯 | Category B (乙) | XJ01MAM134B002010181000 | NHSA |
| 河北凯威恒诚制药有限公司 | 国药准字H20249459 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010183007 | NHSA |
| 陕西丽彩药业有限公司 | 国药准字H20233221 | 250ml∶盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010183540 | NHSA |
| 厦门伯马药业有限公司 | 国药准字H20243011 | 250ml∶盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010183544 | NHSA |
| 哈尔滨三联药业股份有限公司 | 国药准字H20233958 | 250ml∶盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010183546 | NHSA |
| 贵州阜康仁制药有限公司 | 国药准字H20243201 | 250ml∶盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010183571 | NHSA |
| 江苏睿实生物科技有限公司 | 国药准字H20249077 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010183832 | NHSA |
| 安徽康融药业有限公司 | 国药准字H20244544 | 250ml∶盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯 | Category B (乙) | XJ01MAM134B002010184003 | NHSA |
| 重庆药谷制药有限公司 | 国药准字H20265222 | 250ml∶盐酸莫西沙星(按 C₂₁H₂₄FN₃O₄计)0.4g与氯化钠 2.0g | Category B (乙) | XJ01MAM134B002010184756 | NHSA |
| 辽宁民康制药有限公司 | 国药准字H20264052 | 250ml∶盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010201227 | NHSA |
| 江苏正大丰海制药有限公司 | 国药准字H20183412 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010201521 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H20234493 | 250ml∶盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010201631 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20244974 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010202662 | NHSA |
| 石家庄四药有限公司 | 国药准字H20183411 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010202763 | NHSA |
| 赤峰源生药业有限公司 | 国药准字H20234509 | 250ml∶盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010203871 | NHSA |
| 山东齐都药业有限公司 | 国药准字H20193111 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010204145 | NHSA |
| 重庆圣华曦药业股份有限公司 | 国药准字H20243346 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010209568 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20223606 | 250ml:盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010209910 | NHSA |
| Bayer Vital GmbH | 国药准字J20140110 | 250ml:莫西沙星0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010278271 | NHSA |
| 安徽康融药业有限公司 | 国药准字H20244544 | 250ml∶盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯 | Category B (乙) | XJ01MAM134B002010284003 | NHSA |
| 辽宁民康制药有限公司 | 国药准字H20264052 | 250ml∶盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002010301227 | NHSA |
| 河北天成药业股份有限公司 | 国药准字H20244974 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002010302662 | NHSA |
| 安徽康融药业有限公司 | 国药准字H20244544 | 250ml∶盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯 | Category B (乙) | XJ01MAM134B002010384003 | NHSA |
| 天津红日药业股份有限公司 | 国药准字H20203057 | 250ml: 盐酸莫西沙星(按C21H24FN3O4计)0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002020100864 | NHSA |
| 石家庄四药有限公司 | 国药准字H20183411 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002020102763 | NHSA |
| 安徽太阳升药业有限公司 | 国药准字H20203717 | 250ml:莫西沙星0.4g与氯化钠2.0g | Category B (乙) | XJ01MAM134B002020104494 | NHSA |
| 哈尔滨三联药业股份有限公司 | 国药准字H20233958 | 250ml∶盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002020183546 | NHSA |
| 石家庄四药有限公司 | 国药准字H20183411 | 250ml:盐酸莫西沙星(按C₂₁H₂₄FN₃O₄计)0.4g与氯化 | Category B (乙) | XJ01MAM134B002030102763 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 10 filings and 9 distinct first applicants.
Supplement 4 · Generic 6
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏长江药业有限公司 | CYHB2601556 | Supplement | 2026/08/17 | Not stated by source | CDE |
| 广东大翔制药有限公司 | CYHS2602161 | Generic | 2026/08/31 | Not stated by source | CDE |
| 浙江都邦药业股份有限公司 | CYHS2601488 | Generic | 2026/06/24 | Not stated by source | CDE |
| 湖北广济药业股份有限公司;武汉福星生物药业有限公司 | CYHS2601381 | Generic | 2026/06/11 | Not stated by source | CDE |
| 安徽省先锋制药有限公司;安徽丰原药业股份有限公司淮海药厂 | CYHS2601272 | Generic | 2026/06/04 | Not stated by source | CDE |
| 信合援生制药股份有限公司 | CYHS2503938 | Generic | 2025/11/13 | Not stated by source | CDE |
| Bayer Vital GmbH;Fresenius Kabi Italia S. R. L. | JYHB2500578 | Supplement | 2025/10/31 | Not stated by source | CDE |
| Bayer Vital GmbH;Fresenius Kabi Italia S. R. L. | JYHB2500577 | Supplement | 2025/10/31 | Not stated by source | CDE |
| 厦门伯马药业有限公司;广东大翔制药有限公司 | CYHB2500884 | Supplement | 2025/04/29 | Not stated by source | CDE |
| 湖北津药药业股份有限公司 | CYHS2501076 | Generic | 2025/03/15 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 4 filings and 4 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 广东大翔制药有限公司 | CYHS2602161 | Generic | 2026/08/31 | Not stated by source | CDE |
| 浙江都邦药业股份有限公司 | CYHS2601488 | Generic | 2026/06/24 | Not stated by source | CDE |
| 湖北广济药业股份有限公司;武汉福星生物药业有限公司 | CYHS2601381 | Generic | 2026/06/11 | Not stated by source | CDE |
| 安徽省先锋制药有限公司;安徽丰原药业股份有限公司淮海药厂 | CYHS2601272 | Generic | 2026/06/04 | Not stated by source | CDE |
API registrations
Non-component matches: 0 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/08/31Accepted
-
2026/08/17Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Moxifloxacin Hydrochloride And Sodium Chloride Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy